Top in hem/onc: Systemic anticancer treatment; family-friendly medical training policies
Click Here to Manage Email Alerts
A recent study published in JAMA Oncology showed the use of aggressive cancer treatment at the end of life has not decreased but rather shifted from chemotherapy to immunotherapy.
Kerin Adelson, MD, an associate professor of medicine, chief quality officer and deputy chief medical officer for Yale Cancer Center and Smilow Cancer Hospital, told Healio that more patients are being offered targeted therapies and immunotherapies as their health is declining “as a sort of ‘Hail Mary’ or last-ditch effort.” It was the top story in hematology/oncology last week.
Another top story was about new recommendations from the Association of Women Surgeons advocating for family-friendly policies that balance education during medical training with personal and family needs.
Read these and more top stories in hematology/oncology below:
Systemic anticancer treatment at end of life shifts to immunotherapy, still raises concern
Increased awareness of the quality-of-life harm and financial burden associated with continued cancer treatment at the end of a patient’s life has led professional societies to promote reduced systemic anticancer therapy at this stage. Read more.
Organization advocates for family-friendly guidelines during medical training for women
The Association of Women Surgeons has released new recommendations that support the balance of surgical education with personal and family needs. Read more.
BMI linked to safety of checkpoint inhibitors among patients with advanced cancer
High BMI appeared to be associated with increased risk for any-grade immune-related adverse events among a cohort of patients with advanced cancer undergoing treatment with immune checkpoint inhibitors. Read more.
Asian, Black patients with lung cancer face longer wait times to radiation treatment
Asian and Black patients with lung cancer experienced longer delays to radiation treatment than their white counterparts, according to study results published in Health Equity. Read more.
ODAC: Single-arm trial data will suffice for dostarlimab in rectal cancer subgroup
Data from a pair of single-arm clinical trials will be sufficient to illustrate the benefits and risks of dostarlimab-gxly for a subgroup of patients with rectal cancer, according to the FDA’s Oncologic Drugs Advisory Committee. Read more.